Review of the clinical evidence for interferon β 1a (Rebif^®) in the treatment of multiple sclerosis

References

• AntonettiFFinocchiaroOMasciaMA comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosisJ Interferon Cytokine Res2002221181412581490
   PubMed Web of Science ®Google Scholar
• BaumKNehrigCSchörnerWLong-term follow-up of MS:disease activity detected clinically and by MRIActa Neurol Scand19908219162270747
   PubMed Web of Science ®Google Scholar
• BensonKHartzAJA comparison of observational studies and randomized, controlled trialsN Engl J Med200034218788610861324
   PubMed Web of Science ®Google Scholar
• BertolottoAGilliFSalaAEvaluation of bioavailability of three types of IFN-β in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantificationJ Immunol Methods20012561415211516761
   PubMed Web of Science ®Google Scholar
• BertolottoADeisenhammerFGalloPImmunogenicity of interferon beta:differences among productsJ Neurol2004251Suppl 21524
   Google Scholar
• BiernackiKAntelJPBlainMInterferon beta promotes nerve growth factor secretion early in the corse of multiple sclerosisArch Neurol20056211924
   Google Scholar
• BonavitaSDinacciDLavorgnaLTreatment of multiple sclerosis with interferon beta in clinical practice:2-year follow-up data from the South Italy Mobile MRI ProjectNeurol Sci2006273658
   Web of Science ®Google Scholar
• CaraccioNDardanoAManfredoniaFLong-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy:predictive factors of thyroid disease development and durationJ Clin Endocrinol Metab20059041334715811929
   PubMed Web of Science ®Google Scholar
• CohenRAKesslerHRFisherMThe expanded disability status scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosisJ Neurol Sci199311513258482974
   PubMed Web of Science ®Google Scholar
• ComiGFilippiMBarkofFEffect of early treatment on conversion to definite multiple sclerosis:a randomized studyLancet200135715768211377645
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet200235912213111955556
   PubMed Web of Science ®Google Scholar
• ConcatoJShahNHorwitzRIRandomized, controlled trials, observational studies, and the hierarchy of research designN Engl J Med200034218879210861325
   PubMed Web of Science ®Google Scholar
• ConfavreuxCVukusicSMoreauTRelapses and progression of disability in multiple sclerosisN Engl J Med20003431430811078767
   PubMed Web of Science ®Google Scholar
• de AndresCAristimunoCde Las HerasVInterferon beta-1a therapy enhances CD4+ regulatory T-cell function:an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosisJ Neuroimmunol20071822041117157927
   PubMed Web of Science ®Google Scholar
• De StefanoNNarayananSPelletiesDEvidence of early axonal damage in patients with multiple sclerosis [abstract]Neurology199952Suppl 2378
   Google Scholar
• Dhib-JalbutSMechanisms of action of interferons and glatiramer acetate in multiple sclerosisNeurology2002238 Suppl 4S3911971121
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPEvery-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis:results of a 2-year prospective randomised multicentre study (INCOMIN)Lancet200235914536011988242
   PubMed Web of Science ®Google Scholar
• FilippiMRovarisMIngleseMInterferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis:a randomized, double-blind, placebo-controlled trialLancet200436414899615500893
   PubMed Web of Science ®Google Scholar
• FrancisGSGrumserYAltieriEHepatic reactions during treatment with interferon-β-1a:incidence and clinical significanceDrug Saf2003268152712908850
   PubMed Web of Science ®Google Scholar
• EtemadifarMJanghorbaniMShaygannejadVComparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosisActa Neurol Scand2006113283716629762
   PubMed Web of Science ®Google Scholar
• European Study Group on Interferon beta-1b in Secondary Progressive MSPlacebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosisLancet1998352149179820296
   PubMed Web of Science ®Google Scholar
• GalboizYShapiroSLahatNMatrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patientsAnn Neurol2001504435111601495
   PubMed Web of Science ®Google Scholar
• GhezziAAmatoMPCapobiancoMImmunomodulatory Treatment of Early onset MS Group. Disease-modifying drugs in childhood-juvenile multiple sclerosis:results of an Italian co-operative studyMult Scler200511420416042224
   PubMed Web of Science ®Google Scholar
• GhezziAAmatoMPCapobiancoMImmunomodulatory Treatment of Early-onset MS (ITEMS) Group. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a:long-term resultsNeurol Sci2007281273217603763
   PubMed Web of Science ®Google Scholar
• GiorelliMDe BlasiADefazioGDifferential regulation of membrane bound and solubile ICAM 1 in human endothelium and blood mononuclear cells:effects of interferon beta-1aCell Commun Adhes200292597212745437
   PubMed Web of Science ®Google Scholar
• GiovannoniGBarbarashOLJaberAReduced immunogenicity with a new formulation of interferon-beta-1a (Rebif):24 week results of a phase IIIb trial study [abstract]Mult Scler200612Suppl 1192
   Google Scholar
• GoodkinDENorth American Study GroupInterferon beta-1b in secondary progressive MS:clinical and MRI results of a 3-year randomized controlled trial [abstract]Neurology2000542352
   Web of Science ®Google Scholar
• HaasJFirzlaffMTwenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)Eur J Neurol2005124253115885045
   PubMed Web of Science ®Google Scholar
• HartungHPMunschauer IIIFSchellekensHSignificance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis:expert opinions based on Proceedings of an International Consensus ConferenceEur J Neurol20051258860116053466
   PubMed Web of Science ®Google Scholar
• HarzheimMStepien-MeringMSchroderRThe expression of microfilament-associated cell-cell contacts in brain endothelial cells is modified by IFN-beta1a (Rebif)J Interferon Cytokine Res2004247111615684738
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosisAnn Neurol199639285948602746
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosisN Eng J Med2000343898904
   PubMed Web of Science ®Google Scholar
• JuniPAltmanDGEggerMSystematic reviews in health care:assessing the quality of controlled trialsBr Med J200132342611440947
   PubMed Web of Science ®Google Scholar
• KapposLMoeriDRadueEWPredictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis:a meta-analysis. Gadolinium MRI Meta-analysis GroupLancet1999353964910459905
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology2006671242916914693
   PubMed Web of Science ®Google Scholar
• KapposLTraboulseeACostantinescuCLong-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology2006679445317000959
   PubMed Web of Science ®Google Scholar
• KapposLFreedmanMSPolmanCHBENEFIT Study GroupEffect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:a 3-year follow-up analysis of the BENEFIT studyLancet20073703899717679016
   PubMed Web of Science ®Google Scholar
• Koch-HenriksenNSorensenPSChristensenTA randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisNeurology20066610566016510769
   PubMed Web of Science ®Google Scholar
• KortewegTTintoreMUitdehaagBMRI criteria for dissemination in space in patients with clinically isolated syndromes:a multicentre follow-up studyLancet Neurol20065221716488377
   PubMed Web of Science ®Google Scholar
• KoziolJALuceroASipeJCResponsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trialCan J Neurol Sci199926283910563213
   PubMed Web of Science ®Google Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis:an expanded disability status scale (EDSS)Neurology1983331444526685237
   PubMed Web of Science ®Google Scholar
• LiDKBPatyDWMagnetic resonance imaging results of the PRISMS trial:a randomized, double-blind, placebo-controlled study of interferon-b1a in relapsing-remitting multiple sclerosisAnn Neurol19994619720610443885
   PubMed Web of Science ®Google Scholar
• LiDKBZhaoGJPatyDWRandomized controlled trial of interferon-beta-1a in secondary progressive MS:MRI results [abstract]Neurology200156Suppl 3148911236759
   PubMed Web of Science ®Google Scholar
• LimmrothVMalessaRZettl UkJQuality Assessment in Multiple Sclerosis Therapy (QUASIMS).A comparison of interferon beta therapies for relapsing-remitting multiple sclerosisJ Neurol2007254677717273808
   PubMed Web of Science ®Google Scholar
• LiuCBlumhardtLDRandomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analyzed by area under disability/time curvesJ Neurol Neurosurg Psychiatry199967451610486390
   PubMed Web of Science ®Google Scholar
• LiuCBlumhardtLDRandomized, double-blind, placebo-controlled study of subcutaneous interferon beta 1a in relapsing-remitting multiple sclerosis:a categorical disability trend analysisMult Scler20028101411936481
   PubMed Web of Science ®Google Scholar
• LublinFDBaierMCutterGEffect of relapses on development of residual deficit in multiple sclerosisNeurology20036115283214663037
   PubMed Web of Science ®Google Scholar
• MalucchiSSalaAGilliFNeutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosisNeurology2004622031715184610
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis:guidelines from the International Panel on the diagnosis of multiple sclerosisAnn Neurol200150121711456302
   PubMed Web of Science ®Google Scholar
• MilaneseCLa MantiaLPalumboRA post-marketing study on interferon b 1b and 1a treatment in relapsing-remitting multiple sclerosis:different response in drop-outs and treated patientsJ Neurol Neurosurg Psychiatry20037416899214638892
   PubMed Web of Science ®Google Scholar
• MillerDHRudgePJohnsonGSerial gadolinium enhanced magnetic resonance imaging in multiple sclerosisBrain1988111927393401689
   PubMed Web of Science ®Google Scholar
• MonzaniFCaraccioNDardanoAThyroid autoimmunity and dysfunction associated with type I interferon therapy. ReviewClin Exp Med2004319921015103510
   PubMed Web of Science ®Google Scholar
• MurdochDLyseng-WilliamsonKASubcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosisDrugs200565129531215916455
   PubMed Web of Science ®Google Scholar
• NoseworthyJHVandervortMKWongCJInterrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trialNeurology19904097152189084
   PubMed Web of Science ®Google Scholar
• O’RiordanJIThompsonAJKingsleyDPThe prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-upBrain19981214955039549525
   PubMed Web of Science ®Google Scholar
• PaolilloAPozzilliCGiugniEA 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-betaEur J Neurol200296455512453081
   PubMed Web of Science ®Google Scholar
• PanitchHGoodinDSFrancisGfor the EVIDENCE Study Group and the University of British Columbia MS/MRI Research GroupRandomized, comparative study of interferon beta-1a treatment regimens in MS. The EVIDENCE trialNeurology200259149650612451188
   PubMed Web of Science ®Google Scholar
• PattenSBMetzLMInterferon β-1a and depression in relapsing-remitting multiple sclerosis:an analysis of depression data from the PRISMS clinical trialMult Scler20017243811548984
   PubMed Web of Science ®Google Scholar
• PattenSBMetzLMInterferon β1a and depression in secondary progressive MS:Data from the SPECTRIMS TrialNeurology200259744612221168
   PubMed Web of Science ®Google Scholar
• PatyDWMagnetic resonance imaging in the assessment of disease activity in multiple sclerosisCan J Neurol Sci198815266723208208
   PubMed Web of Science ®Google Scholar
• PohlDRostasyKGärtnerJHanefeldFTreatment of early onset multiple sclerosis with subcutaneous interferon beta-1aNeurology2005658889015753430
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCEdanGDiagnostic criteria for multiple sclerosis:2005 revisions to the “McDonald Criteria”Ann Neurol200558840616283615
   PubMed Web of Science ®Google Scholar
• PoserCMPatyDWScheinbergLNew diagnostic criteria for multiple sclerosis:guidelines for research protocolsAnn Neurol198313227316847134
   PubMed Web of Science ®Google Scholar
• PRISMS study groupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by interferon β-1a in Subcutaneously in Multiple Sclerosis) Study GroupLancet199835214985049820297
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group, University of British Columbia MS/MRI Analysis GroupPRISMS-4:long term tolerability of interferon beta-1a in relapsing MSNeurology20015616283611425926
   PubMed Web of Science ®Google Scholar
• RiceGPAPasznerBOgerJThe evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1bNeurology1999521277910214759
   PubMed Web of Science ®Google Scholar
• RieckmannPO’ConnorPFrancisGSHaematological effects of interferon-β-1a (Rebif) therapy in multiple sclerosisDrug Saf2004277455615350158
   PubMed Web of Science ®Google Scholar
• RìoJTintoreMNosCTéllezNInterferon beta in relapsing-remitting multiple sclerosis – an eight years experience in a specialist multiple sclerosis centerJ Neurol200525279580015772741
   PubMed Web of Science ®Google Scholar
• RothuizenLEBuclinTSpertiniFInfluence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markersJ Neuroimmunol1999991314110496186
   PubMed Web of Science ®Google Scholar
• RovarisMConfavreuxCFurlanRSecondary progressive multiple sclerosis:current knowledge and future challengesLancet Neurol200653435416545751
   PubMed Web of Science ®Google Scholar
• RudickRAAntelJConfavreuxCClinical outcomes assessment in multiple sclerosisAnn Neurol199640469798797541
   PubMed Web of Science ®Google Scholar
• RudickRALeeJCSimonJSignificance of T2 lesions in multiple sclerosis:a 13-year longitudinal studyAnn Neurol2006602364216786526
   PubMed Web of Science ®Google Scholar
• RunkelLMeierWPepinskyStructural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta)Pharm Res1998156416499587963
   PubMed Web of Science ®Google Scholar
• SimonJHJacobsLDCampionMand the Multiple Sclerosis Collaborative Research Group (MSCRG)Magnetic resonance studies of intramuscular interferon b-1a for relapsing multiple sclerosisAnn Neurol19984379879450771
   PubMed Web of Science ®Google Scholar
• SPECTRIMS Study Group (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS)Randomized controlled trial of interferon-beta-1a in secondary progressive MSNeurology20015615051311402107
   PubMed Web of Science ®Google Scholar
• SättlerMBDemerIWilliamsSKEffects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditionsExp Neurol20062011728116764858
   PubMed Web of Science ®Google Scholar
• StürzebecherSMaibauerRHeunerAPharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteersJ Interferon Cytokine Res19991912576410574618
   PubMed Web of Science ®Google Scholar
• TenembaumSNSeguraMJInterferon beta-1a treatment in childhood and juvenile-onset multiple sclerosisNeurology2006675111316775230
   PubMed Web of Science ®Google Scholar
• The IFNβ Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis:I. Clinical results of a multicenter,randomized, double-blind, placebo-controlled trial. The IFNβ Multiple Sclerosis Study GroupNeurology199343655618469318
   PubMed Web of Science ®Google Scholar
• The Once Weekly Interferon for MS Study GroupEvidence of interferon beta-1a dose response in relapsing-remitting MS:the OWIMS Study. The Once Weekly Interferon for MS Study GroupNeurology536798610489026
   PubMed Web of Science ®Google Scholar
• ThompsonAJPolmanCHMillerDHPrimary progressive multiple sclerosisBrain19971201085969217691
   PubMed Web of Science ®Google Scholar
• TrappBDRanschoffRMFisherNeurodegeneration in multiple sclerosis:relationship to neurological disabilityNeuroscientist199954857
   Web of Science ®Google Scholar
• TremlettHLOgerJElevated aminotransferases during treatment with interferon-beta for multiple sclerosis:actions and outcomesMult Scler20041029830115222695
   PubMed Web of Science ®Google Scholar
• TremlettHLOgerJHepatic injury liver monitoring and the beta-interferons for multiple sclerosisJ Neurol2004251129730315592724
   PubMed Web of Science ®Google Scholar
• TremlettHLYoshidaEMOgerJLiver injury associated with the β-interferons for MS: a comparison between the three productsNeurology2004626283114981183
   PubMed Web of Science ®Google Scholar
• TrojanoMPaolicelliDZimatoreGBThe IFNbeta treatment of multiple sclerosis (MS) in clinical practice. The experience at the MS center of Bari, ItalyNeurol Sci200526Suppl 417982
   Web of Science ®Google Scholar
• TuohyVKYuMYinLThe epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosisImmunol Rev1998164931009795767
   PubMed Web of Science ®Google Scholar
• VartanianTSolberg SorensenPRiceGImpact of neutralising antibodies on the clinical efficacy of interferon beta in multiple sclerosisJ Neurol2004251Suppl 22530
   Google Scholar
• WagstaffAJGoaKLRecombinant interferon-β-1a:a review of its therapeutic efficacy in relapsing-remitting multiple sclerosisBiodrugs1998104719418020616
   PubMed Web of Science ®Google Scholar
• WeinshenkerBGThe natural history of multiple sclerosisNeurol Clin199513119467739500
   PubMed Web of Science ®Google Scholar
• WeinshenkerBGBassBRiceGPAThe natural history of multiple sclerosis:a geographically based study: I. Clinical course and disabilityBrain1989112133462917275
   PubMed Web of Science ®Google Scholar
• WeinshenkerBGRiceGPANoseworthyJHThe natural history of multiple sclerosis:a geographically based study 4 Applications to planning and interpratation of clinical therapeutic trialsBrain19911141057672043941
   PubMed Web of Science ®Google Scholar
• WilliamsGJWittPLComparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AvonexJ Interferon Cytokine Res199818967759858319
   PubMed Web of Science ®Google Scholar
• WingerchukDMWeinshenkerBGThe natural history of multiple sclerosis. Implications for trial designCurr Opin Neurol199912345910499179
   PubMed Web of Science ®Google Scholar
• YongVWChabotSStuveOInterferon beta in the treatment of multiple sclerosis:mechanisms of actionNeurology19985168299748010
   PubMed Web of Science ®Google Scholar